Navigation Links
nanoTox COO Greg King Advises Nanotech Companies to View Safety Concerns as an Opportunity to Gain Consumer Trust
Date:4/7/2010

nanoTox COO Greg King responded to the AOL News series, “The Nanotech Gamble,” with advice for nano-product companies on how to turn concerns over nanotechnology into consumer relations wins.

Austin, TX (Vocus) -- Responding to a series of AOL News articles questioning the oversight of nanotechnology product safety (http://www.aolnews.com/category/nanotech/), nanoTox COO Greg King said that nano-product companies will need to confront possible negative perceptions directly to avoid the kinds of public outcry experienced by bioengineered food companies in the past.

“It’s in people’s nature to fear the unknown,” said King. “And while companies may not be able to educate everyone in the complexities of nanotechnology, they can turn safety concerns to their advantage by being transparent about its use in their products, documenting their careful research and emphasizing concern over human and environment health.”

King was responding to AOL News and Pulitzer Prize-winning reporter Andrew Schneider, who published a series entitled “The Nanotech Gamble” which explored possible risks that may accompany nanotechnology research and product development. Schneider’s series was greeted with concern by most in the U.S. nanoproduct industry.

“Schneider’s articles expresses quite well the public’s concern about nanomaterials.” King added. “No new technology gains wide consumer acceptance until potential safety concerns are addressed and resolved.

“Companies wanting to successfully commercialize products that contain nanomaterials will need to address those safety concerns. This is especially true for nanoproducts that have direct human contact, such as textiles, foods, medic
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Burrill Merchant Banking Advises NPS on Phase III Licensing Agreement
2. Burrill Merchant Banking Advises Faes Farma on Bilastine Licensing Agreement
3. White Paper Advises Pharma Manufacturers on How to Select an Aseptic Fill/Finish Contractor, Avoid the Most Common Mistakes
4. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
5. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
6. KTA Capital Advises SpringTree Global Investors on an AU$25.5 Million Investment in Prima BioMed Ltd
7. Stevens to host Nanoscience/Nanotechnology & Corrosion symposium, Nov. 13
8. NASA technology forms the basis for a new nanotechnology company
9. Superbugs, shapes and nanotechnology
10. Siemens and Xintek Form Joint Venture to Develop Nanotechnology-Enabled Multi-Pixel X-ray Tubes
11. Nanotech could make solar energy as easy and cheap as growing grass
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... February 27, 2015 The fully ... (Nexera UC) can sequentially analyze up to 48 ... with high-sensitivity detection of targets by mass spectrometry. ... to fulfill the measurement requirements of a wide ... products, drug delivery and search for disease biomarkers, ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE MKT: ... of biosimilar therapeutics, today announced that it will be ... Marquis on March 2 nd at 3pm PST. Patrick ... a panel discussing the current state of the biosimilar ... . For more information on CALBIO ...
(Date:2/27/2015)... Francisco, CA (PRWEB) February 27, 2015 ... joining forces on February 28 with patients and health ... raise awareness for Rare Disease Day®. Rare Disease ... diseases and calling attention to the special challenges faced ... around them. , “Cytokinetics is proud to stand alongside ...
(Date:2/27/2015)... Feb. 27, 2015   PureTech , a science ... commercializing disruptive products and technologies in the healthcare sector, ... former CEO and Member of the Board of Directors ... "It,s has been a pleasure to know Chris ... we will be working together more closely now," said ...
Breaking Biology Technology:Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4
... Therapeutics Inc. (TSX:,LOR, AMEX: LRP) ("Lorus" or ... research and development of pharmaceutical products and,technologies ... progress made in,the Virulizin(R) development program, including ... Virulizin(R) mode of action and the issuance ...
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... Vice President, Global Supply Chain and,Sustainment Engineering. He ... of Alexza,s global supply chain strategy to,support the ... lead program, AZ-004 (Staccato(R) loxapine) is in,Phase 3 ...
... ... Advisory Board --, SAN DIEGO, July 9 ... has received regulatory approval to,begin a Phase 2a proof-of-concept clinical trial ... arthritis, is a,painful and debilitating disease caused by abnormally elevated levels ...
Cached Biology Technology:Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 2Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 3Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 4Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 5Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 6Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering 2Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering 3Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 2Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 3Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 4
(Date:2/5/2015)... Jan. 27, 2015   Marvin Test ... deployed, innovative test solutions for military, aerospace, ... of its TS-323 GENASYS Test Platform ... (LMSSC). GENASYS is a high-performance PXI-based system ... applications that require performance functional testing. GENASYS ...
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying ... power and potential for genomic science as a means ... disease prevention and treatment.  I was honored to participate ... government-funded precision medicine program. Since the ... science of genomics—from the first sequenced genome of a ...
(Date:1/22/2015)... - Today, FindBiometrics, the leading source of biometrics industry news, interviews ... design. "When we launched FindBiometrics 12 years ago ... , founder and CEO of FindBiometrics. "Now it,s maturing very ... key players on a very broad scale.  We are known ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... potential for an outbreak of the phenomenon commonly called ... spring and summer, according to researchers with the Woods ... (NCSU). This advisory is based in part ... Alexandrium fundyense the algae notorious ...
... international team of researchers from China and the United ... Early Cretaceous rocks in the southern part of the ... Jiayuguan, Gansu Province, China. Two of their discoveries represent ... in technical publications published on-line in the Proceedings ...
... in French . Scientists at the ... Japan along with researchers from McGill University and other ... are controlled in mammals. Three years of intensive research by ... publication of several milestone scientific papers in Nature Genetics ...
Cached Biology News:Researchers report 'moderately large' potential for red tide outbreak in Gulf of Maine region 2Researchers report 'moderately large' potential for red tide outbreak in Gulf of Maine region 3Researchers report 'moderately large' potential for red tide outbreak in Gulf of Maine region 4Field Museum paleontologist leads study on two new dinosaurs from China 2Field Museum paleontologist leads study on two new dinosaurs from China 3Field Museum paleontologist leads study on two new dinosaurs from China 4Major international study challenges notions of how genes are controlled in mammals 2
... early protein. Can detect ... exhibiting an intranuclear inclusion staining ... 6-24 hours. These antibodies ... staining. No other nuclear ...
MAb to Vasopressin Preservative: NaN3...
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
MMP-2 / MMP-9 Inhibitor IV is a potent, selective, slow binding and mechanism based inhibitor of human gelatinases. • Molecular weight: 306.4 • Molecular Formula: C(15)H(14)O(3)S(2). &bul...
Biology Products: